Table 11.
Parameter | Male rats | Female rats | ||||
---|---|---|---|---|---|---|
Control | 11% GMO | 33% GMO | Control | 11% GMO | 33% GMO | |
IPR concanavalin A | 69.72 ± 28.69 | 52.84 ± 9.36 | 47.57 ± 11.45 | 33.80 ± 19.33 | 34.77 ± 19.62 | 38.36 ± 21.08 |
IPR phytohemagglutinin | 27.69 ± 3.85 | 21.53 ± 3.06* | 21.85 ± 7.39 | 15.71 ± 9.41 | 15.95 ± 11.82 | 18.15 ± 6.69 |
IPR pokeweed mitogen | 14.15 ± 5.21 | 13.24 ± 2.75 | 11.93 ± 3.63 | 9.44 ± 4.91 | 9.96 ± 7.22 | 11.46 ± 3.85 |
IPR 5 ng Cry1Ab/ml | 1.02 ± 0.16 | 1.09 ± 0.23 | 0.92 ± 0.19 | 1.93 ± 2.26 | 0.73 ± 0.20 | 0.79 ± 0.20 |
IPR 50 ng Cry1Ab/ml | 1.02 ± 0.13 | 1.04 ± 0.21 | 0.80 ± 0.12* | 1.50 ± 1.26 | 0.81 ± 0.21 | 0.82 ± 0.22 |
IPR 500 ng Cry1Ab/ml | 1.10 ± 0.24 | 1.01 ± 0.24 | 0.98 ± 0.15 | 1.31 ± 0.72 | 0.88 ± 0.33 | 0.86 ± 0.23 |
IPR 50 ng non-GM maize protein/ml | 0.93 ± 0.11 | 0.99 ± 0.06 | 0.91 ± 0.20 | 0.96 ± 0.10 | 0.87 ± 0.23 | 1.12 ± 0.54 |
IPR 500 ng non-GM maize protein/ml | 0.80 ± 0.06 | 0.86 ± 0.14 | 0.77 ± 0.19 | 0.96 ± 0.18 | 0.92 ± 0.29 | 0.78 ± 0.18 |
IPR 5 µg non-GM maize protein/ml | 0.77 ± 0.24 | 0.68 ± 0.20 | 0.64 ± 0.12 | 0.98 ± 0.27 | 0.86 ± 0.14 | 0.96 ± 0.40 |
IPR 50 ng GM maize protein/ml | 1.00 ± 0.14 | 0.90 ± 0.09 | 0.82 ± 0.13 | 0.88 ± 0.14 | 0.83 ± 0.23 | 0.86 ± 0.10 |
IPR 500 ng GM maize protein/ml | 0.85 ± 0.09 | 0.92 ± 0.11 | 0.76 ± 0.14 | 0.99 ± 0.23 | 0.84 ± 0.17 | 0.82 ± 0.20 |
IPR 5 µg GM maize protein/ml | 0.97 ± 0.17 | 0.70 ± 0.16* | 0.75 ± 0.09 | 0.83 ± 0.22 | 0.83 ± 0.26 | 0.93 ± 0.26 |
Spleen cells were incubated for 3 days with concanavalin A, phytohemagglutinin or pokeweed mitogen and for 6 days with Cry1Ab, the near isogenic non-GM maize protein extract or the GM maize protein extract in the given amounts. The table lists the indexed proliferative response (IPR) = proliferative response of stimulated cells/proliferative response of non-stimulated cells, expressed as cage mean ± SD (five cages; n = 10 rats)
*Statistically significant difference to the control value based on the 95% confidence interval of the SES